| Venous gas embolism during foam sclerotherapy of saphenous veins despite recommended treatment modifications. | |
| | |
MedLine Citation:
|
PMID: 21087951 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate the effectiveness of methods proposed to prevent venous gas embolism during foam sclerotherapy. METHODS: Transthoracic echocardiography was performed concurrent with ultrasound-guided sclerotherapy (UGS) of great or small saphenous veins. A volume of 2.5 mL of 3% sodium tetradecyl sulphate foam was prepared following the Tessari method and injected slowly 5-10 cm away from saphenous junctions. The procedure was repeated with modifications including using a 5 µm filter to generate microfoam, carbon dioxide as the foaming gas, leg elevation before or after the injection and immobility post-treatment. RESULTS: Bubbles entered the right heart in less than 60 seconds and continued for up to 50 minutes despite all treatment modifications. None of the patients had a patent foramen ovale and none developed any neurological or cardiac symptoms. CONCLUSION: Bubble emboli entered the heart during foam UGS of saphenous veins despite all treatment modifications and low volumes of foam used. |
| | |
Authors:
|
K Parsi |
Publication Detail:
|
Type: Journal Article Date: 2010-11-18 |
Journal Detail:
|
Title: Phlebology / Venous Forum of the Royal Society of Medicine Volume: 26 ISSN: 1758-1125 ISO Abbreviation: Phlebology Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-06-21 Completed Date: 2011-10-13 Revised Date: 2011-11-10 |
Medline Journal Info:
|
Nlm Unique ID: 9012921 Medline TA: Phlebology Country: England |
Other Details:
|
Languages: eng Pagination: 140-7 Citation Subset: IM |
Affiliation:
|
Sydney Skin and Vein Clinic, Sydney, Australia. kparsi@ozemail.com.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Embolism, Air
/
etiology*,
ultrasonography Female Humans Male Saphenous Vein* Sclerosing Solutions / adverse effects*, therapeutic use* Sclerotherapy* Sodium Tetradecyl Sulfate / adverse effects*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Sclerosing Solutions; 1191-50-0/Sodium Tetradecyl Sulfate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ranking prognosis markers in cancer genomic studies.
Next Document: Cycloplegic and noncycloplegic refractions of Chinese neonatal infants.